VisualSonics Announces Next Generation In Vivo Imaging Technology to Make Strides in Cancer Risk Reduction, Early Detection, ...
April 04 2011 - 2:05PM
Business Wire
VisualSonics Inc., a leader in real time, in vivo,
high-resolution micro-imaging systems and a wholly-owned subsidiary
of SonoSite Inc., (Nasdaq:SONO), is demonstrating the
recently announced Vevo® LAZR Photoacoustics Imaging system at the
American Association of Cancer Research’s annual conference (April
2-6, 2011, Orlando, FL).
The new system has been designed for use in pre-clinical
research and could herald major breakthroughs in cancer research;
however, human applications of the technology are envisioned in the
near future.
“The Vevo LAZR is a crucial breakthrough with wide ranging
implications for cancer research,” said Dr. Emelianov. “In recent
years, the fight against cancer has centered on stopping growth
using drugs (anti-angiogenesis therapeutics, for instance). If
angiogenesis can be stopped or prevented from occurring, tumor
growth can be controlled and significantly reduce harm to their
hosts.”
Furthermore, the ability to see the effect that a drug is having
on the tumor growth is an invaluable asset in the development of
cancer therapeutics. In practical terms, this means researchers
will be able to observe tumor biology in a living host organism
(mice and rats) without having to biopsy the actual tumor itself.
Currently, researchers are often required to rely on ex vivo
techniques such as histology and immunohistochemistry to obtain
molecular information inside a tumor. The in vivo approach reduces
the amount of animals required for research studies by allowing the
same animal to be followed throughout the disease development and
treatment.
Dr. Emelianov continued, “Being able to look at molecular level
cell physiology, and to do so in a living organism, will greatly
facilitate our understanding of how cancer spreads from the micro
to the macro level, giving unparalleled insights into how tumors
grow and metastasize within human tissue.”
“The Vevo LAZR photoacoustics system is a breakthrough in vivo
imaging technology,” said Anil Amlani, VisualSonics’ President and
CEO. “Advancements featured in this product will enable oncology
researchers to accelerate their research into understanding the
inner workings of the cancerous cell and the host tissue in which
it resides. The ability to conduct this microscopic level research
in a living organism, non-invasively and in real-time, will help
our customers to turn groundbreaking science into lifesaving care
at an even greater speed.”
“The launch of the Vevo LAZR technology further demonstrates our
commitment in providing game changing imaging technology to advance
pre-clinical research,” said Kevin M. Goodwin, SonoSite’s President
and CEO. “We are confident that the photoacoustics technology will
provide never-before-seen insights into cancer research and will
have a strong impact on the discovery of new therapeutics.”
The Vevo LAZR system supports VisualSonics’ continuous efforts
to provide researchers with innovative solutions to improving
pre-clinical research. Applications for the Vevo LAZR system range
from lymph node imaging, study of hemoglobin and oxygen saturation,
and targeted imaging of tumor biomarkers. In addition to cancer
biology, this cutting-edge imaging system will benefit other areas
of research such as diabetes, neurosciences, as well as
developmental and reproductive biology.
Researchers are invited to experience a demonstration of the
Vevo LAZR system by visiting VisualSonics at booth #2171 at
AACR.
About VisualSonics
VisualSonics is the world leader in real time, in vivo,
high-resolution micro imaging systems designed specifically for
preclinical research and a wholly-owned subsidiary of SonoSite,
Inc. (Nasdaq:SONO). The Company’s cutting edge technologies
allow researchers at the world’s most prestigious pharmaceutical
and biotechnology companies, hospitals and universities to conduct
research in cardiovascular, cancer, neurobiology and developmental
biology areas. The micro imaging technologies support research
applications that include genetic research, phenotypic studies and
drug development. VisualSonics micro imaging platforms combine
high-resolution, real time in vivo imaging at reasonable cost with
ease-of-use and quantifiable results.
About SonoSite
SonoSite, Inc. (www.sonosite.com) is the innovator and world
leader in bedside and point-of-care ultrasound and an industry
leader in ultra high-frequency micro-ultrasound technology and
impedance cardiography equipment. Headquartered near Seattle, the
company is represented by fourteen subsidiaries and a global
distribution network in over 100 countries. SonoSite’s small,
lightweight systems are expanding the use of ultrasound across the
clinical spectrum by cost-effectively bringing high-performance
ultrasound to the point of patient care.
Forward-looking Information and the
Private Litigation Reform Act of 1995
Certain statements in this press release relating to the
expected benefits of the Vevo LAZR Photoacoustics Imaging
technology, including market acceptance of products incorporating
Vevo LAZR Photoacoustics Imaging technology and new market and
sales opportunities for SonoSite, and other statements regarding
future results are “forward-looking statements” for the purposes of
the safe harbor provisions of the Private Securities Litigation
Reform Act of 1995. These forward-looking statements are based on
the opinions and estimates of our management at the time the
statements are made and are subject to risks and uncertainties that
could cause actual results to differ materially from those expected
or implied by the forward-looking statements. These statements are
not guaranties of future performance and are subject to known and
unknown risks and uncertainties and are based on potentially
inaccurate assumptions. Factors that could cause actual results to
differ from the forward-looking statements include: the risk that
the technology will not yield the expected potential benefits,
including the risk that we are unsuccessful in achieving market
acceptance of this technology, and the potential
for competitive technologies, as well as other factors
contained in the Item 1A. “Risk Factors” section of SonoSite,
Inc.’s most recent Annual Report on Form 10-K filed with the
Securities and Exchange Commission. We caution readers not to place
undue reliance upon these forward-looking statements that speak
only as to the date of this release. We undertake no obligation to
publicly revise any forward-looking statements to reflect new
information, events or circumstances after the date of this release
or to reflect the occurrence of unanticipated even.
Sonos (NASDAQ:SONO)
Historical Stock Chart
From Sep 2024 to Oct 2024
Sonos (NASDAQ:SONO)
Historical Stock Chart
From Oct 2023 to Oct 2024